In the present report, we found this SNP to be associated with a reduction in breast cancer risk, with these risk effects remaining significant even in particular patient subgroups including women who were ER-negative, PR-negative, or who had reached menopause at a later age. This evidence concerns the gene ESR1 and breast carcinoma.